Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Ribupatide

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

Fujian Shengdi Pharmaceutical Co · Phase 3 · Completed · Enrollment 567

NCT06396429

ArmPopulationDoseWeeksEstimandWeight change
Treatment group A: HRS9531 injectionObesity or overweightn/rn/rn/rn/r
Treatment group B: HRS9531 injectionObesity or overweightn/rn/rn/rn/r
Treatment group C: HRS9531 injectionObesity or overweightn/rn/rn/rn/r
Placebo injectionObesity or overweightn/rn/rn/rn/r